Lamtor5 Knockout cell line (4T1)
Catalog Number: KO01175
Price: Online Inquiry
Catalog Number: KO01175
Price: Online Inquiry
Product Information | |
---|---|
Product Name | Lamtor5 Knockout cell line (4T1) |
specification | 1*10^6 |
Storage and transportation | Dry ice preservation/T25 live cell transportation. |
Cell morphology | Epithelioid, adherent cell |
Passage ratio | 1:3~1:4 |
species | Mouse |
Gene | Lamtor5 |
Gene ID | 68576 |
Build method | Electric rotation method / virus method |
Mycoplasma testing | Negative |
Cultivation system | 88%RPMI-1640+10% FBS+1%Glutamax+1%Sodium Pyruvate |
Parental Cell Line | 4T1 |
Quality Control | Genotype: Lamtor5 Knockout cell line (4T1) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |
Gene Information | |
---|---|
Gene Official Full Name | late endosomal/lysosomal adaptor, MAPK and MTOR activator 5provided by MGI |
Also known as | XIP; Hbxip; 1110003H18Rik |
Gene Description | Predicted to contribute to guanyl-nucleotide exchange factor activity and molecular adaptor activity. Predicted to be involved in several processes, including negative regulation of cysteine-type endopeptidase activity; positive regulation of interleukin-8 production; and positive regulation of intracellular signal transduction. Predicted to act upstream of or within positive regulation of NF-kappaB transcription factor activity. Predicted to be located in cytosol. Predicted to be part of FNIP-folliculin RagC/D GAP and Ragulator complex. Predicted to be active in lysosomal membrane. Is expressed in embryo. Orthologous to human LAMTOR5 (late endosomal/lysosomal adaptor, MAPK and MTOR activator 5). [provided by Alliance of Genome Resources, Apr 2025] |
Expression | Ubiquitous expression in kidney adult (RPKM 71.3), large intestine adult (RPKM 37.1) and 28 other tissues See more |
We develop gene knockout solutions tailored to customer requirements and the condition of the target gene.
Cas9 Protein
Cas9 mRNA sgRNA
Cas9 Plasmid
Cas9 Virus
A – Exon KO
gRNAs are designed in the introns flanking the exon, targeting non-multiple-of-3 base deletions in the exon, resulting in frameshift mutations.
B - Frameshift KO
gRNAs are designed within the exon, creating non-multiple-of-3 base deletions to induce frameshift mutations.
C - Complete KO
The entire gene coding sequence is deleted, achieving large-scale knockout effects.
KO Strategy Design
CRISPR Plasmid/Lentiviral Vector Construction
Lentiviral Packaging
Cell Transfection/Lentiviral Infection
Drug Selection
Cell Cryopreservation
Quality Control
Sequencing Validation
Monoclonal Cell Line Generation
Pool Efficiency Validation
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.